PRODUCT MONOGRAPH

PrNoxivent™

nitric oxide for inhalation

100 ppm and
800 ppm

Medical Gas

Praxair Canada Inc.
1 City Centre Drive, Suite 1200,
Mississauga, ON L5B 1M2

Control Number: 175320
Date of Preparation: January 22, 2016
PRODUCT MONOGRAPH

PrNoxivent™
nitric oxide for inhalation
100 ppm and 
800 ppm
Medical Gas

ACTIONS AND CLINICAL PHARMACOLOGY

Nitric oxide is a compound produced by many cells of the body. It relaxes vascular smooth muscle by binding to the heme moiety of cytosolic guanylate cyclase, activating guanylate cyclase and increasing intracellular levels of cyclic guanosine 3’,5’-monophosphate, which then leads to vasodilation. When inhaled, nitric oxide produces selective pulmonary vasodilation. Nitric oxide is very rapidly inactivated by binding to hemoglobin. Thus, delivered via inhalation, nitric oxide improves V/Q matching and is a selective pulmonary vasodilation agent.

Inhaled nitric oxide appears to increase the partial pressure of arterial oxygen (PaO₂) by dilating pulmonary vessels in better ventilated areas of the lung, redistributing pulmonary blood flow away from lung regions with low ventilation/perfusion (V/Q) ratios toward regions with normal ratios.

Effects on Pulmonary Vascular Tone in PPHN: Persistent pulmonary hypertension of the newborn (PPHN) occurs as a primary developmental defect or as a condition secondary to other diseases such as meconium aspiration syndrome (MAS), pneumonia, sepsis, hyaline membrane disease, congenital diaphragmatic hernia (CDH), and pulmonary hypoplasia. In these states, pulmonary vascular resistance (PVR) is high, which results in hypoxemia secondary to right-to-left shunting of blood through the patent ductus arteriosus and foramen ovale. Inhalation of nitric oxide reduces the oxygenation index (OI= mean airway pressure in cm H₂O x fraction of inspired oxygen concentration [FiO₂] x 100 divided by systemic arterial concentration in mm Hg [PaO₂]) and increases PaO₂.

Clinical Studies
The efficacy of nitric oxide has been investigated in term and late pre-term newborns with hypoxic respiratory failure, resulting from a variety of etiologies, who had oxygenation index (OI) measurements of ≥ 25 cm H₂O/mm Hg.
In a post-hoc subgroup analysis of data from the NINOS and CINRGI studies, the clinical benefit measured by the receipt of ECMO was greater for the subgroups of patients who did not meet the study ECMO criteria at study entry (NINOS) or whose baseline OI was less than 40 cm H\textsubscript{2}O/mm Hg (CINRGI).

**NINOS study:** The Neonatal Inhaled Nitric Oxide Study (NINOS) group conducted a double-blind, randomized, placebo-controlled, multicenter trial in 235 neonates (≥ 34 weeks gestational age) with hypoxic respiratory failure and OI values of ≥ 25 cm H\textsubscript{2}O/mm Hg.

The objective of the study was to determine whether inhaled nitric oxide would reduce the occurrence of death and/or initiation of extracorporeal membrane oxygenation (ECMO) in a prospectively defined cohort of term or late pre-term neonates with hypoxic respiratory failure unresponsive to conventional therapy. Hypoxic respiratory failure was caused by meconium aspiration syndrome (MAS; 49%), pneumonia/sepsis (21%), idiopathic primary pulmonary hypertension of the newborn (PPHN; 17%), or respiratory distress syndrome (RDS; 11%). Infants up to 14 days of age (mean, 1.7 days) with a mean PaO\textsubscript{2} of 46 mm Hg and a mean oxygenation index (OI) of 43 cm H\textsubscript{2}O/mm Hg were initially randomized to receive 100% O\textsubscript{2} with (n=114) or without (n=121) 20 ppm nitric oxide for up to 14 days. Response to study drug was defined as a change from baseline in PaO\textsubscript{2} 30 minutes after starting treatment (full response = > 20 mm Hg, partial = 10-20 mm Hg, no response = <10 mm Hg). Neonates with a less than full response were evaluated for a response to 80 ppm nitric oxide or control gas. The primary results for the intent-to-treat (ITT) population are presented in Table 1.

<table>
<thead>
<tr>
<th>Table 1</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Summary of Clinical Results from NINOS Study</strong></td>
</tr>
<tr>
<td><strong>ITT Population</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Death or ECMO(^a,b)</td>
</tr>
<tr>
<td>Death</td>
</tr>
<tr>
<td>ECMO</td>
</tr>
</tbody>
</table>

\(^a\) Extracorporeal membrane oxygenation  
\(^b\) Death or need for ECMO was the study’s primary end point

Although the incidence of death by 120 days of age was similar in both groups (NO, 14%; control, 17%), significantly fewer infants in the nitric oxide group required ECMO compared with controls (39% vs. 55%, p = 0.014). The combined incidence of death and/or initiation of ECMO showed a significant advantage for the nitric oxide treated group (46% vs. 64%, p = 0.006).

The primary efficacy endpoint assessed by the actual gas received was evaluated in a post-hoc analysis and is presented in Table 2.
Table 2
Summary of Clinical Results from NINOS Study
Actual-Gas-Received Population

<table>
<thead>
<tr>
<th>Response</th>
<th>Control (n=116)</th>
<th>NO (n=119)</th>
<th>P value</th>
<th>Absolute rate reduction (%)</th>
<th>Relative rate reduction (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Death or ECMO&lt;sup&gt;a,b&lt;/sup&gt;</td>
<td>72 (62%)</td>
<td>57 (48%)</td>
<td>0.036</td>
<td>-14.2</td>
<td>-22.8</td>
</tr>
<tr>
<td>Death</td>
<td>18 (16%)</td>
<td>18 (15%)</td>
<td>1.000</td>
<td>Not applicable</td>
<td>Not applicable</td>
</tr>
<tr>
<td>ECMO</td>
<td>62 (53%)</td>
<td>48 (40%)</td>
<td>0.050</td>
<td>-13.1</td>
<td>-24.5</td>
</tr>
</tbody>
</table>

<sup>a</sup> Extracorporeal membrane oxygenation  
<sup>b</sup> Death or need for ECMO was the study’s primary end point

The response rate (full response, partial response, no response) to 20 ppm inhaled nitric oxide for the actual-gas-received population was also determined in a post-hoc analysis and is presented in Table 3.

Table 3
Response Rate to Study Gas
Actual-Gas-Received Population

<table>
<thead>
<tr>
<th>Response</th>
<th>Placebo (n=112)</th>
<th>NO (n=117)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full (&gt;20 torr increase in PaO2 30 minutes)</td>
<td>16 (14.3%)</td>
<td>58 (49.6%)</td>
</tr>
<tr>
<td>Partial (10-20 torr increase in PaO2 30 minutes)</td>
<td>13 (11.6%)</td>
<td>17 (14.5%)</td>
</tr>
<tr>
<td>No (&lt;10 torr increase in PaO2 30 minutes)</td>
<td>83 (74.1%)</td>
<td>42 (35.9%)</td>
</tr>
</tbody>
</table>

Data also showed that only 5.5% of neonates who did not respond, or partially responded to the inhaled nitric oxide therapy at a 20 ppm dose were converted to full response with 80 ppm inhaled nitric oxide, indicating no additional benefit of inhaled nitric oxide at 80 ppm. These findings are consistent with conclusions from the original ITT population.

The rate of death or receipt of ECMO was assessed in a post-hoc analysis of the actual-gas-received population by initial response to 20 ppm inhaled nitric oxide, and is presented in Table 4.
Table 4
ECMO Receipt by Initial Response Status
Actual-Gas-Received Population

<table>
<thead>
<tr>
<th>Response</th>
<th>Rate of Death or ECMO</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo (n=112)</td>
<td>NO (n=117)</td>
<td>P Value*</td>
<td>Absolute rate reduction (%)</td>
</tr>
<tr>
<td>Fully responded in the first 30 minutes**</td>
<td>8/16 (50%)</td>
<td>15/58 (25.9%)</td>
<td>0.076</td>
<td>-24.1</td>
</tr>
<tr>
<td>Partial or no response in the first 30 minutes</td>
<td>63/96 (65.6%)</td>
<td>40/59 (67.8%)</td>
<td>0.862</td>
<td>2.2</td>
</tr>
</tbody>
</table>

* p-value from Fisher’s 2-tailed exact test
** full response was defined as ≥ 20 mm Hg increase in PaO₂ after 30 minutes of gas treatment

These results showed that the rate of death or receipt of ECMO between treatment groups differed according to the initial response to 20 ppm inhaled nitric oxide, indicating that patients who initially did not fully respond to inhaled nitric oxide therapy in the first 30 minutes of treatment did not benefit significantly from the therapy.

The nitric oxide group had significantly greater increases in PaO₂ and greater decreases in the OI and the alveolar-arterial oxygen gradient than the control group (p<0.001 for all parameters).

No infant had study drug discontinued for toxicity. Inhaled nitric oxide had no detectable effect on mortality. The adverse events collected in the NINOS trial occurred at similar incidence rates in both treatment groups. (See Adverse Reactions).

CINRGI study: This study was a double-blind, randomized, placebo-controlled, multicenter trial of 186 term and late pre-term neonates (≥ 34 weeks gestational age) with pulmonary hypertension and hypoxic respiratory failure, with OI values of ≥ 25 cm H₂O/mm Hg. The primary objective of the study was to determine whether nitric oxide would reduce the receipt of ECMO in these patients. Hypoxic respiratory failure was caused by MAS (35%), idiopathic PPHN (30%), pneumonia/sepsis (24%), or RDS (8%). Patients with a mean PaO₂ of 54 mm Hg and a mean OI of 44 cm H₂O / mm Hg were randomly assigned to receive either 20 ppm nitric oxide (n=97) or nitrogen gas (placebo; n=89) in addition to their ventilatory support. Patients who exhibited a PaO₂ >60 mm Hg and a pH < 7.55 were weaned to 5 ppm nitric oxide or placebo. The maximum duration

Praxair Canada Inc.
of nitric oxide therapy was 96 hours. The primary results from the CINRGI study are presented in Table 5.

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>Nitric Oxide</th>
<th>P value</th>
<th>Absolute rate reduction (%)</th>
<th>Relative rate reduction (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ECMO a,b</td>
<td>51/89 (57%)</td>
<td>30/97 (31%)</td>
<td>&lt; 0.001</td>
<td>-26.4</td>
<td>-46.0</td>
</tr>
<tr>
<td>Death</td>
<td>5/89 (6%)</td>
<td>3/97 (3%)</td>
<td>0.48</td>
<td>Not applicable</td>
<td>Not applicable</td>
</tr>
</tbody>
</table>

a Extracorporeal membrane oxygenation  
b ECMO was the primary end point of this study

Significantly fewer neonates in the nitric oxide group required ECMO compared to the control group (31% vs. 57%, p<0.001). While the number of deaths were similar in both groups (nitric oxide, 3%; placebo, 6%), the combined incidence of death and/or receipt of ECMO was decreased in the nitric oxide group (33% vs. 58%, p<0.001).

In addition, the nitric oxide group had significantly improved oxygenation as measured by PaO2, OI, and alveolar-arterial gradient (p<0.001 for all parameters). Of the 97 patients treated with nitric oxide, 2 (2%) were withdrawn from study drug due to methemoglobin levels > 4%. The frequency and number of adverse events reported were similar in the two study groups (See Adverse Reactions).
**INDICATION AND CLINICAL USE**

*Noxivent™*, in conjunction with ventilatory support and other appropriate agents, is indicated for the treatment of term and late pre-term (≥ 34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.

The safety and effectiveness of nitric oxide have been established in a population receiving other therapies for hypoxic respiratory failure, including vasodilators, intravenous fluids, bicarbonate therapy, and mechanical ventilation.

In clinical trials, no efficacy has been demonstrated with the use of nitric oxide in patients with congenital diaphragmatic hernia.

An adequate pharmacovigilance study, over a minimum of 5 years, will be carried out to confirm the long-term effects associated with the use of inhaled nitric oxide in neonates.

**CONTRAINDICATIONS**

In patients with the rare cardiovascular defect in which the systemic oxygenation is wholly dependent on extra-pulmonary right-to-left shunting, the use of *Noxivent™* has the potential to decrease right-to-left blood flow, which, in this condition, is potentially fatal.

**WARNINGS**

**Left to Right Shunting**

Treatment with *Noxivent™* might aggravate cardiac insufficiency in a situation with left-to-right shunting. This is due to unwanted pulmonary vasodilation caused by inhaled nitric oxide, resulting in a further increase of already existing pulmonary hyperperfusion. It, therefore, is recommended that prior to the administration of nitric oxide, pulmonary artery catheterization or echocardiographic examination of central hemodynamics be performed.

**PRECAUTIONS**

**General**

Initiate any alternative therapies as soon the infant's condition demands, regardless of the response or lack of response to *Noxivent™*.

If it is judged that clinical response is inadequate at 4-6 hours after starting *Noxivent™*, the following should be considered. For patients who are to be referred to another hospital, to prevent worsening of their condition on acute discontinuation of *Noxivent™*, the availability of nitric oxide during transport should be assured. Rescue, such as ECMO where available, should be considered based on continued deterioration or failure to improve, defined by local hospital criteria.

Long-term effects, particularly with regard to pulmonary and neurodevelopmental outcomes associated with nitric oxide, have not been established beyond 18-24 months.
The 18-24 months follow-up study of NINOS subjects was based on a relatively small number of patients treated with placebo (n=84) and inhaled nitric oxide (n=88), and the one-year follow-up data of CINRGI subjects was based on 71 patients in the placebo and 74 patients in the inhaled nitric oxide groups. In view of the potential long-term sequelae associated with the underlying condition, persistent pulmonary hypertension of the newborn, and the unknown long-term effects of nitric oxide, it is recommended that these babies be monitored long-term regarding pulmonary, neurodevelopmental, growth and auditory outcomes.

Health professionals at neonatal units that administer Noxivent™ should be properly trained (see Training in Administration) and familiar with the instructions for use of the nitric oxide delivery system. They should have access to supplier-provided 24 hour/365 days per year technical support on the delivery and administration of Noxivent™.

In order to avoid errors in the delivery of Noxivent™, health professionals that administer nitric oxide should ensure that the mode and make of mechanical ventilation being utilized are compatible with the Noxivent™ delivery system.

**Rebound Pulmonary Hypertension following Abrupt Discontinuation**

Noxivent™ should not be discontinued abruptly as it may result in rebound pulmonary hypertension (increase in pulmonary artery pressure and worsening of blood oxygenation). If rebound pulmonary hypertension occurs, reinstate therapy immediately.

Rapid rebound reactions have been described and can precipitate cardiopulmonary collapse, even in patients without substantial oxygenation improvement. The patient should be treated with increased FiO2 and by reinstallment of therapy with Noxivent™. When possible, Noxivent™ should be continued until the underlying disease has resolved. Weaning from Noxivent™ should be performed with caution. See **Dosage and Administration** section.

Deterioration in oxygenation and elevation in pulmonary artery pressure may also occur in neonate with no apparent response to Noxivent™. Again, weaning from Noxivent™ should be performed with caution. See **Dosage and Administration** section.

**Methemoglobinemia**

Neonates are known to have diminished methemoglobin reductase activity compared to adults and could therefore be at greater risk of developing methemoglobinemia. The concentrations of methemoglobin in the blood should be monitored as Noxivent™ is absorbed systemically and the end products of nitric oxide that enter the systemic circulation are predominantly methemoglobin and nitrate. See **Monitoring Methemoglobin** under **Dosage and Administration**.

Methemoglobinemia increases with the dose of nitric oxide. If methemoglobin levels are > 2.5%, the Noxivent™ dose should be decreased and the administration of reducing agent such as methylene blue may be considered. Following discontinuation or reduction of Noxivent™, methemoglobin levels should return to baseline over a period of hours. If methemoglobin levels do not resolve after discontinuation or reduction of
therapy additional measures may be warranted, see Symptoms and Treatment of Overdosage section.

Airway Injury from NO₂
NO₂ rapidly forms in gas mixtures containing nitric oxide and O₂, and nitric oxide may in this way cause airway inflammation and damage. The dose of Noxivent™ should be reduced if the concentration of nitrogen dioxide exceeds 0.5 ppm. See Monitoring Nitrogen Dioxide under Dosage and Administration.

In one study, NO₂ levels were < 0.5 ppm when neonates were treated with placebo, 5 ppm, and 20 ppm nitric oxide over the first 48 hours. The 80 ppm group had a mean peak NO₂ level of 2.6 ppm.

Heart Failure
Patients with left ventricular dysfunction treated with inhaled nitric oxide, even for short durations, experienced serious adverse events (e.g., pulmonary edema, increased pulmonary capillary wedge pressure, worsening of left ventricular dysfunction, systemic hypotension, bradycardia and cardiac arrest). Discontinue Noxivent™ while providing symptomatic care.

Bleeding Time
Animal models have shown that nitric oxide may interact with homeostasis, resulting in an increased bleeding time. Data in adult humans are conflicting. Inhaled nitric oxide has been found to approximately double bleeding time in a limited study in rabbits and humans. However, there has been no statistically significant increase in bleeding complications in randomized controlled trials in term and late pre-term neonates with hypoxic respiratory failure.

Adults
Noxivent™ is not indicated for use in the adult population.

Use in Pregnancy
Animal reproduction studies have not been conducted with inhaled nitric oxide. It is not known if nitric oxide can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Passive exposure to nitric oxide during pregnancy and lactation should be avoided. Noxivent™ is not intended for adults.

Nursing Mothers
Noxivent™ is not indicated for use in the adult population, including nursing mothers. It is not known whether nitric oxide is excreted in human milk.

Pediatric Use
Nitric oxide for inhalation has been studied in a neonatal population up to 14 days of age who were ≥ 34 weeks gestational age. No information about its effectiveness in other age populations is available. Although clinical studies are ongoing, the efficacy and safety of nitric oxide for neonates less than 34 weeks gestational age has not been established. Noxivent™ is not indicated for neonates less than 34 weeks gestational age.
Drug Interactions
Experimental studies have suggested that nitric oxide and nitrogen dioxide may react chemically with surfactant and/or surfactant proteins. No formal drug-interaction studies have been performed, and a clinically significant interaction with other medications used in the treatment of hypoxic respiratory failure cannot be excluded based on the available data. In particular, although there are no data to evaluate the possibility nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with nitric oxide on the risk of developing methemoglobinemia. Nitric oxide has been administered with tolazoline, dopamine, dobutamine, steroids, surfactant, and high-frequency ventilation. Noxivent™ should be used with caution in patients receiving NO donor compounds (e.g. nitroprusside, nitroglycerine, and substances known to increase methemoglobin) because of the potential of methemoglobinemia.

Laboratory Tests
Noxivent™ should be administered with monitoring for PaO₂, methemoglobin, and NO₂. Methemoglobin levels should be measured within one hour after initiation of Noxivent™ therapy and periodically throughout the treatment period using an analyzer, which can reliably distinguish between fetal hemoglobin and methemoglobin. See Monitoring Methemoglobin and Monitoring Nitrogen Dioxide under Dosage and Administration.

ADVERSE REACTIONS

The NINOS and CINRGI studies were not powered to detect statistically significant differences with regards to adverse events between the placebo and inhaled nitric oxide treatment groups.

In the NINOS trial, treatment groups were similar with respect to the incidence and severity of intracranial hemorrhage, Grade IV hemorrhage, periventricular leukomalacia, cerebral infarction, seizures requiring anticonvulsant therapy, pulmonary hemorrhage, or gastrointestinal hemorrhage. The following post-hoc analysis shows the distribution of selected adverse events in the NINOS trial for the actual-drug-received population (n=235).

**Selected adverse events in the NINOS trial**
Actual-Gas-Received Population

<table>
<thead>
<tr>
<th>Adverse Events</th>
<th>Placebo (n=116)</th>
<th>iNO (all doses)** (n=119)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Air Leak</td>
<td>14 (12.1%)</td>
<td>18 (15.1%)</td>
</tr>
<tr>
<td>Cerebral or Intracranial Infarct***</td>
<td>21 (18.1%)</td>
<td>21 (17.6%)</td>
</tr>
<tr>
<td>Seizures Requiring Treatment</td>
<td>22 (19.0%)</td>
<td>18 (15.1%)</td>
</tr>
<tr>
<td>Periventricular leukomalacia (PVL)***</td>
<td>3 (2.6%)</td>
<td>6 (5.0%)</td>
</tr>
<tr>
<td>Other CNS Insult</td>
<td>15 (12.9%)</td>
<td>11 (9.2%)</td>
</tr>
<tr>
<td>Pulmonary Hemorrhage***</td>
<td>5 (4.3%)</td>
<td>5 (4.2%)</td>
</tr>
<tr>
<td>Prolonged Oozing from Heel Stick</td>
<td>9 (7.8%)</td>
<td>8 (6.7%)</td>
</tr>
<tr>
<td>GI Bleeding</td>
<td>1 (0.9%)</td>
<td>1 (0.8%)</td>
</tr>
<tr>
<td>New Intraventricular hemorrhage (IVH)***</td>
<td>6 (5.2%)</td>
<td>5 (4.2%)</td>
</tr>
</tbody>
</table>
* The NINOS study prospectively planned to collect only adverse events of particular interest; all adverse events were not systematically collected.

**Patients received maximum 20 ppm or 80 ppm inhaled nitric oxide as per the study protocol.

*** In a post-hoc analysis, among patients who did not receive ECMO and considering only the 20 ppm dose, there were numerical increases in the following outcomes: cerebral/intracranial infarct, periventricular leukomalacia, pulmonary hemorrhage, and new intraventricular hemorrhage although there are limitations to such post-hoc analyses.

The table below shows adverse events with an incidence of at least 5% on nitric oxide in the CINRGI study, and that were more common on nitric oxide than on placebo.

<table>
<thead>
<tr>
<th>Adverse Events</th>
<th>Placebo (n=89)</th>
<th>Inhaled NO (n=97)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypotension</td>
<td>9 (10%)</td>
<td>13 (13%)</td>
</tr>
<tr>
<td>Withdrawal</td>
<td>9 (10%)</td>
<td>12 (12%)</td>
</tr>
<tr>
<td>Atelectasis</td>
<td>8 (9%)</td>
<td>9 (9%)</td>
</tr>
<tr>
<td>Hematuria</td>
<td>5 (6%)</td>
<td>8 (8%)</td>
</tr>
<tr>
<td>Hyperglycemia</td>
<td>6 (7%)</td>
<td>8 (8%)</td>
</tr>
<tr>
<td>Sepsis</td>
<td>2 (2%)</td>
<td>7 (7%)</td>
</tr>
<tr>
<td>Infection</td>
<td>3 (3%)</td>
<td>6 (6%)</td>
</tr>
<tr>
<td>Stridor</td>
<td>3 (3%)</td>
<td>5 (5%)</td>
</tr>
<tr>
<td>Cellulitis</td>
<td>0 (0%)</td>
<td>5 (5%)</td>
</tr>
</tbody>
</table>

Data from a post-hoc analysis among patients in the CINRGI study who did not receive ECMO (not randomized sample) showed that inhaled nitric oxide patients had numerical increases in the following adverse events: tachycardia, hypokalemia, infection, fever, cellulites, coagulation disorder, hemorrhage, deafness, and hematuria.

In the NINOS study, doses of inhaled nitric oxide up to 80 ppm and duration of therapy up to 14 days were permitted. Also the delivery devices used in the NINOS study were not able to provide a consistent dose of inhaled nitric oxide, on the other hand, the standardized delivery devices were used in CINRGI study to provide a consistent dose of inhaled nitric oxide. Consequently, 42.9% of patients in the NINOS study (at maximum dose of 20 ppm) exceeded the proposed 0.5 ppm threshold for NO₂ while only 9.7% of patients exceeded this threshold in the CINRGI study. Similarly, 26.4% patients in the NINOS study and 3.6% in the CINRGI study exceeded the proposed 2.5% threshold for methemoglobin level. These results indicate the importance of using standard delivery devices for the safe administration of inhaled nitric oxide therapy.

**Long-term Safety**

Follow-up exams were performed at 18-24 months for the infants enrolled in the NINOS study. In the infants with available follow-up, there were no statistically significant differences between the two treatment groups with respect to their mental, motor, audiologic, visual or neurologic evaluations. Seventy-four and one-half percent (74.5%) of infants in inhaled nitric oxide group and 76.1% in placebo group were classified as neurologically normal. Mental development of the infants, as assessed by the Bayley scale of mental developmental index (MDI) was similar between the treatment groups. However, a post-hoc analysis of adverse events for the actual-gas-received population showed some numerical differences between treatment groups (see the table below).
Adverse Events at 18-24 months of follow-up in NINOS subjects
Actual-gas-received population

<table>
<thead>
<tr>
<th>Adverse Events</th>
<th>Placebo</th>
<th>INO (all doses)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gait Disturbance (gait functional, gait device required, and no independent walking)</td>
<td>15/84 (17.9%)</td>
<td>22/88 (25.0%)</td>
</tr>
<tr>
<td>Cerebral Palsy Present</td>
<td>8/84 (9.5%)</td>
<td>11/88 (12.5%)</td>
</tr>
<tr>
<td>At Least One Seizure Since Discharge</td>
<td>12/85 (14.1%)</td>
<td>5/88 (5.7%)</td>
</tr>
<tr>
<td>Sensorineural Loss</td>
<td>6/75 (8.0%)</td>
<td>8/73 (11.0%)</td>
</tr>
<tr>
<td>Mean Bayley PDI STD</td>
<td>94.4 ± 17.9</td>
<td>85.0 ± 21.3</td>
</tr>
<tr>
<td>PDI &lt; 50</td>
<td>3/76 (3.9%)</td>
<td>11/83 (13.3%)</td>
</tr>
</tbody>
</table>

*Patients received maximum 20 ppm or 80 ppm iNO as per the study protocol.

Long-term effects of nitric oxide, particularly with regard to pulmonary and neurodevelopmental outcomes, have not been established beyond 18-24 months.

Data from the one-year follow-up of CINRGI study subjects (85% follow-up rate) showed that patients in the inhaled nitric oxide group had a higher percentage of hearing loss (4%) than those in the placebo group (0%)\(^1\). Additionally, patients treated with inhaled nitric oxide had higher percentages of cerebral palsy (4%) than those treated with placebo (1%).

Data from the one-year follow-up of 145 patients of the original 155 infants in the non-pivotal study INO-01/02 showed that 23% of patients in the inhaled nitric oxide group and 14% in placebo group had severe impairment of overall assessment of neurologic status at one year. The patients in this study were treated with three doses of inhaled nitric oxide (5 ppm, 20 ppm and 80 ppm). However, there was no clear dose–response relationship between the adverse event and the inhaled nitric oxide dose.

The overall 5-year follow-up rate of NINOS and CINRGI study subjects was only 25%. The 5-year follow-up data were based on 43 patients in the placebo group and 55 patients in the inhaled nitric oxide group. Patients treated with inhaled nitric oxide had a significantly higher incidence of gait disturbance at 5-year follow-up (16% in inhaled nitric oxide group versus 2% in placebo group, \(p=0.04\)). Additionally, the percentage of vision problems, recurrent non-febrile seizures was numerically higher among inhaled nitric oxide patients. Due to the 25% follow-up rate, valid conclusions cannot be made.

**Post-marketing Experience**
In addition to adverse events reported from clinical trials, the following adverse drug reactions have been identified in neonates (≤ 1 month of age):

**Cardiac Disorders:** bradychardia following abrupt discontinuation of therapy.

**Respiratory, Thoracic and Mediastinal Disorders:** hypoxia following abrupt discontinuation of therapy.

**Vascular Disorders:** hypotension following abrupt discontinuation of therapy.
Accidental Exposure: Chest discomfort, dizziness, dry throat, dyspnea, and headache have been reported in hospital staff after accidental exposure.

SYMPTOMS AND TREATMENT OF OVERDOSAGE

Overdosage with Noxivent™ will be manifest by elevations in methemoglobin and NO₂. Elevated NO₂ may cause acute lung injury. Elevations in methemoglobinemia reduce the oxygen delivery capacity of the circulation.

Methemoglobinemia that does not resolve after reduction or discontinuation of therapy can be treated with intravenous vitamin C, intravenous methylene blue, or blood transfusion, based upon the clinical situation.

For management of a suspected drug overdose, contact your regional Poison Control Centre.

DOSAGE AND ADMINISTRATION

Dosage
The minimum effective dose for the indication has not been optimally identified in randomized clinical trials. The initial dose of Noxivent™ should be as low as possible and in no cases higher than 20 ppm for no more than 4 hours. In cases of failure to respond to Noxivent™ at 4-6 hours after starting therapy, further steps should be considered. Between 4-24 hours attempts should be made to decrease the dose as quickly as possible to 5 ppm. Treatment with aggressive attempts to lower the dose to 5 ppm, should be maintained until underlying oxygen saturation has resolved but for no more than 96 hours of therapy at which time the neonate should be weaned from Noxivent™ therapy. See Precautions: General section.

Efficacy and safety of nitric oxide have not been established beyond 96 hours of use. The duration of therapy is variable, but typically less than four days.

An initial dose of 20 ppm was used in the NINOS and CINRGI trials. In CINRGI, patients whose oxygenation improved with 20 ppm were dose-reduced to 5 ppm as tolerated at the end of 4 hours of treatment. In the NINOS trial, patients whose oxygenation failed to improve on 20 ppm could be increased to 80 ppm, but those patients did not then increase their PaO₂ on the higher dose. The risk of methemoglobinemia and elevated NO₂ levels increases significantly when Noxivent™ is administered at doses >20 ppm.

Weaning/Discontinuation
The Noxivent™ dose should not be discontinued abruptly as it may result in an increase in pulmonary artery pressure (PAP) and/or worsening of blood oxygenation (PaO₂). Deterioration in oxygenation and elevation in PAP may also occur in neonates with no apparent response to Noxivent™.
Starting as soon as possible and within 4-24 hours of therapy, the dose should be weaned to 5 ppm provided that arterial oxygenation is adequate at this lower dose. *Noxivent™* therapy should be maintained at 5 ppm until there is improvement in the neonate’s oxygenation such that the FiO$_2$ (fraction of inspired oxygen) < 0.60.

When the decision is made to discontinue *Noxivent™* therapy, the dose should be lowered and steps taken to minimize the frequently encountered transient drop in PaO$_2$ noted for 10 to 60 minutes after discontinuation of *Noxivent™*. One regimen that accomplished this is to reduce the dose to 1 ppm for 30 to 60 minutes. If there is no change in oxygenation during administration of *Noxivent™* at 1 ppm, the FiO$_2$ should be increased by 10%, the *Noxivent™* is discontinued, and the neonates monitored closely for signs of hypoxemia. If oxygenation falls > 20%, *Noxivent™* therapy should be resumed at 5 ppm and discontinuation of *Noxivent™* therapy should be reconsidered after 12 to 24 hours. Infants who cannot be weaned off *Noxivent™* by 4 days should undergo careful diagnostic work-up for other diseases.

**Administration Parameters**

**Training in Administration**
Healthcare professionals involved in the care of patients on *Noxivent™* therapy need to be trained by the manufacturer of the nitric oxide delivery system or have support from personnel trained by the manufacturer in the following key elements of nitric oxide delivery:

1. theory of device operation
2. delivery system setup including connections to gas cylinders and the breathing circuit
3. pre-use procedures (series of steps and tests to verify that the delivery system is fully functional and ready for safe use)
4. gas sensor calibration
5. setting or changing of therapeutic nitric oxide concentration
6. use of backup nitric oxide delivery mode (independent of the main delivery system) to ensure un-interrupted delivery of nitric oxide for inhalation
7. changing gas cylinders and purging the system
8. checking and adjusting alarm settings
9. troubleshooting procedures
10. delivery system maintenance schedule and procedures according to manufacturer specifications

**Administration**
Prescription and administration of *Noxivent™* should be supervised by a physician experienced in neonatal intensive care. Prescription and administration should be limited to those neonatal units that have received adequate training in the use of a nitric
oxide delivery system. Noxivent™ should only be delivered according to a neonatologist’s prescription.

Noxivent™ is delivered to the patient via mechanical ventilation after dilution with an oxygen/air mixture using an approved nitric oxide delivery system. The delivery system must provide a constant inhaled Noxivent™ concentration irrespective of the ventilator. With a continuous flow neonatal ventilator, this may be achieved by infusing a low flow of Noxivent™ into the inspiratory limb of the ventilator circuit. Intermittent flow neonatal ventilation may be associated with spikes in nitric oxide concentration. The nitric oxide delivery system for intermittent flow ventilation should be adequate to avoid spikes in nitric oxide concentration.

The inspired Noxivent™ concentration must be measured continuously in the inspiratory limb of the circuit near the patient. The nitrogen dioxide (NO₂) concentration and FiO₂ must also be measured at the same site using calibrated and approved monitoring equipment. For patient safety, appropriate alerts must be set for Noxivent™ (± 2 ppm of the prescribed dose), NO₂ (0.5 ppm), and FiO₂ (± 0.05). The Noxivent™ cylinder pressure must be displayed to allow timely cylinder replacement without inadvertent loss of therapy, and backup cylinders must be available to provide timely replacement. Noxivent™ therapy must be available for manual ventilation such as suctioning, patient transport, and resuscitation.

In the event of a system failure or a wall-outlet power failure, a backup battery power supply and reserve nitric oxide delivery system should be available. The availability of these backups will minimize the risk of loss of Noxivent™ therapy resulting from failure of the primary nitric oxide administration apparatus. The power supply for the monitoring equipment should be independent of the delivery device function.

In order to minimize the risks of hypoxemia associated with acute interruption of drug therapy and accidental exposure, the device should include provision for attachment of two Noxivent™ cylinders which can be used alternately via a manifold, or other means to assure a continuous supply of nitric oxide for normal operation of a primary administration system during replacement of cylinders.

Noxivent™ should be administered with monitoring for PaO₂, methemoglobin, and NO₂.

**Monitoring Methemoglobin**

Neonates are known to have diminished methemoglobin reductase activity compared to adults. Methemoglobin level should be measured within one hour after initiation of Noxivent™ therapy using an analyzer, which can reliably distinguish between fetal hemoglobin and methemoglobin. Although it is unusual for the methemoglobin level to increase significantly if the first level is low, it is prudent to repeat methemoglobin measurements periodically throughout the treatment period. If methemoglobin is > 2.5%, the Noxivent™ dose should be decreased and the administration of reducing agents such as methylene blue may be considered.

**Monitoring Nitrogen Dioxide**

Immediately prior to each patient initiation, proper procedure must be applied to purge the nitric oxide delivery system of NO₂. The NO₂ concentration should be maintained as
low as possible and always < 0.5 ppm. If the NO₂ is > 0.5 ppm, the delivery system should be assessed for malfunction, the NO₂ analyzer should be recalibrated, and the Noxivent™ and/or FiO₂ should be reduced if possible. If there is an unexpected change in Noxivent™ concentration, the delivery system should be assessed for malfunction and the analyzer should be recalibrated.

PHARMACEUTICAL INFORMATION

Drug Substance: Nitric oxide
Proper name: Nitric oxide
Chemical name: Nitric oxide, nitrogen II oxide
Structural formula: NO
Chemical structure: \( \cdot \ddot{N}=\ddot{O} \)
Molecular mass: 30.01 grams
Physical form: gas

Composition:
Noxivent™ (nitric oxide) for inhalation is a gaseous blend of nitric oxide and nitrogen (0.08% and 99.92%, respectively for 800 ppm; 0.01% and 99.99%, respectively for 100 ppm).

Stability and Storage Recommendations:
The shelf life of Noxivent™ is 24 months. Store cylinders at controlled room temperature 15-30 °C.

All regulations concerning handling of pressure vessels must be followed.

Protect the cylinders from shocks, falls, oxidizing and flammable materials, moisture, and sources of heat or ignition.

The installation of a nitric oxide pipeline system with supply station of cylinders, fixed network and terminal units substantially increases the risk of NO₂ formation and delivery to patients and is strongly discouraged.

Transport of cylinders:
The cylinders should be transported with appropriate material in order to protect them from risks of shocks and falls.

Special Instructions:
Used Noxivent™ cylinders are returned to Praxair Canada Inc.

Occupational Exposure
The upper limit of exposure (mean exposure) to nitric oxide for personnel defined by worker’s legislation is 25 ppm for 8 hours (30 mg/m³) in most countries and the corresponding limit for NO₂ is 2 - 3 ppm (4-6 mg/m³).
**Availability of Dosage Forms**

*Noxivent™* (nitric oxide) for inhalation is supplied in aluminum cylinders as a compressed gas under high pressure (2000 pounds per square inch gauge [psig]) and is available in the following sizes:

Size AD portable aluminum cylinders containing 348 liters at STP of nitric oxide gas in 800 ppm concentration in nitrogen (delivered volume 341 liters).

Size AD portable aluminum cylinders containing 348 liters at STP of nitric oxide gas in 100 ppm concentration in nitrogen (delivered volume 341 liters).

Size AQ aluminum cylinders containing 2239 liters at STP of nitric oxide gas in 800 ppm concentration in nitrogen (delivered volume 2197 liters).

Size AQ aluminum cylinders containing 2237 liters at STP of nitric oxide gas in 100 ppm concentration in nitrogen (delivered volume 2196 liters).
PHARMACOLOGY

Human Pharmacokinetics

The safety of short-term inhalation of nitric oxide (NO) (40 ppm for 2 hours) in 12 healthy volunteers demonstrated no notable effects on systolic and diastolic blood pressures, heart rate, respiratory rate, or peripheral oxygen saturation. Nor were significant effects on hematologic and chemistry laboratory assessments noted (CTN-NO- 93-006). Normal, healthy adult volunteers studies of inhaled nitric oxide at doses of up to 128 ppm, that is greater than any dose used clinically, demonstrate no clinically significant methemoglobinemia. Maximum levels of methemoglobin are achieved after 3 to 5 hours on NO inhalation and pharmacokinetic modeling was performed on the raw data by Ohmeda (RDR 0076). In both healthy subjects and patients with severe heart failure, the metabolism of NO was found to be dependent on the oxygenation of red cell hemoglobin (CTN-NO-93-008). The data indicate that the inactivation of NO occurred in the red blood cells and suggested that oxyhemoglobin acted as an oxygen donor to the NO molecule in its conversion to nitrate. The fraction of NO inactivated via stoichiometric conversion to nitrate and methemoglobin seemed to be determined by the oxyhemoglobin/hemoglobin ratio in the red blood cells. A study of healthy adult volunteers found that not all of the absorbed NO initially forms methemoglobin, but up to approximately 14% of absorbed NO may be converted directly to nitrogen oxides, which have a volume of distribution equal to about one third of body weight and a clearance similar to the glomerular filtration rate (Young et al²). Data for another study in healthy adult men indicated that the conversion of NO into NO₃⁻ is a major metabolic pathway for inhaled NO in humans and that over 70% of inhaled NO is excreted as NO₃⁻ in the urine (Westfelt et al³).

Pharmacokinetics in Neonates:

Methemoglobin formation is expected during treatment with inhaled nitric oxide in the proposed dose range and should be dose-dependent. Patients not receiving inhaled nitric oxide typically have methemoglobin levels of 0.2 to 1%. The primary problem with elevated methemoglobin is that it reduces the total oxygen-carrying capacity of blood. The acceptable levels for methemoglobin are controversial. Most investigators have used 5 to 10% methemoglobin as the maximum acceptable level.

The mean methemoglobin levels for the Ohmeda INO 01/02 trial are shown in Figure 1. As seen, there is a dose-dependent increase in methemoglobin levels with maximal levels of approximately 5% (the predefined level of methemoglobin at which the inhaled nitric oxide dose was to be reduced) in the 80-ppm inhaled nitric oxide dose group. Doses of 20-ppm or less of inhaled nitric oxide, however, had average values for methemoglobin of approximately 1% or less.
Thirteen of the 37 patients receiving 80-ppm inhaled nitric oxide (35%) in this study developed methemoglobin levels above 7%. The time course for these patients is seen in Figure 2. The mean time to reach their peak level of methemoglobin was 10.5 ± 9.5 hours. Most patients reached this level within the first 18 hours of therapy although one patient did not until 40 hours on inhaled nitric oxide thus emphasizing the need to continue to monitor levels over 48 hours of initiation of therapy. No patient receiving 20-ppm or 5-ppm inhaled nitric oxide in this trial had methemoglobin levels above 7%.
Hemostasis Modifying Agents
Endogenous NO is thought to regulate the platelet cGMP and to have antiaggregatory activity (Radomski et al. 4). There is also controversy whether the combination of inhaled NO and other pharmaceutical compounds that have anti-coagulative properties may influence hemostasis synergistically or additively.

In study ICR 013402, randomized volunteers received either placebo inhalation, or 80 ppm inhaled NO, with or without heparin 5000 E given i.v. at the start of inhalation procedure. In no instance did the combination of inhaled NO + heparin cause a prolonged bleeding time, thus ruling out additive/synergistic effects between inhaled NO and an anti-coagulative agent (heparin).

Pharmacodynamics
In patients who are ‘responders’ to this therapy in terms of improved arterial oxygen tension during mechanical ventilation, the main pharmacodynamic response to inhaled nitric oxide is typically seen within a few minutes from the start of treatment.

The main effect of inhaled nitric oxide is to relax lung vascular smooth muscle, causing dilation of blood vessels and consequently increased blood flow in the region reached by the compound.
Pharmacodynamics in Neonates:
The improvement of arterial oxygen tension in hypoxemic newborns during administration of inhaled nitric oxide is often due to the combined reduction of both extra-pulmonary and intra-pulmonary shunting. The impairment of gas exchange is traditionally estimated by repeated calculations of oxygenation index (OI) in neonates, with OI = 100 x (FiO₂ x MAP)/PaO₂, with MAP = mean airway pressure, FiO₂ = fraction of inspired oxygen, PaO₂ = postductal arterial oxygen tension. Historical control suggests that OI > 40 is correlated to 80% mortality and is often used as the threshold value for rescue with ECMO.

Any therapy with a clinically meaningful impact on hypoxemic respiratory failure should thus cause a significant reduction of OI, preferably a sustained reduction below 40, which would indicate establishment of acceptable oxygenation requiring less aggressive ventilator settings. The sponsor conducted a dose finding study in neonatal patients (CTN-NO-93-003), which demonstrated a rapid (within 10 minutes) improvement in arterial oxygenation already at dose at or below 10 ppm in a majority of neonates.

Animal
From a study in dogs it can be deduced that the lethal concentration is around 640 ppm nitric oxide for 4 hours, whereas, exposures of 320 ppm nitric oxide are non-lethal. (Study SC940065)

TOXICOLOGY

The preclinical safety profile of nitric oxide was assessed in rats in repeat dose inhalation studies up to 2 years in duration. Age-specific nitric oxide-induced toxicity has not been determined, as juvenile animal toxicity studies were not conducted. There are no reproductive animal studies or human studies to evaluate nitric oxide for effects on fertility or harm to the developing fetus. Nitric oxide has demonstrated genotoxicity in some bacterial strains used in the Salmonella (Ames Test), the mouse lymphoma test, Chinese hamster ovary cell test, in vivo exposure in rats, and human lymphocytes.

Inhalation exposures of F344 rats to 20, 10 or 5 ppm NO for 20 hr/day for up two years were examined. The results of this study indicate that there was no evidence of a toxic effect on the respiratory tract or other organs as determined using clinical and ophthalmoscopic observations, examination of tissues at necropsy, organ and body weight changes, clinical pathology, and histopathologic examination of tissues.
## Repeat Dose (Long-Term) Toxicology

<table>
<thead>
<tr>
<th>Reports</th>
<th>Species &amp; Test System</th>
<th>Dose/ Concentration</th>
<th>Study Type &amp; Duration</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>SC940063</td>
<td>Sprague-Dawley rats</td>
<td>0, 80, 200, 300, 400, 500 ppm NO in air</td>
<td>Nose-only inhalation exposures for 6 hrs/day for up to 7 days</td>
<td>No adverse effects below 200 ppm; dose-related increases in metheme above 200 ppm. Histotoxic anoxia due to metheme leading to lethality above 200 ppm.</td>
</tr>
<tr>
<td>RDR-0149 DS</td>
<td>Sprague-Dawley rats</td>
<td>0, 200, NO in air, with 2.2 ppm NO&lt;sub&gt;2&lt;/sub&gt; in 200 ppm NO group</td>
<td>Report of evaluation of respiratory tract at the level of electronmicroscopy from animals exposed for 1 or 7 days</td>
<td>Moderate increase of interstitial edema after 1 day, Slight increase after 7 days. Findings consistent with NO&lt;sub&gt;2&lt;/sub&gt; exposure.</td>
</tr>
<tr>
<td>SC940064</td>
<td>Sprague-Dawley rats</td>
<td>0, 40, 80, 160, 200, 250 ppm NO in air with up to 3.5 ppm NO&lt;sub&gt;2&lt;/sub&gt; in 250 ppm NO group</td>
<td>Nose-only inhalation exposures for 6 hrs/day for 28 days, with 28 day recovery groups</td>
<td>Exposure-system related elevated dosing excursion (32% on day 14-15); lethality at 200 ppm (n=1) and 250 (n=17); dose-related increase in metheme from 160 ppm; metheme levels consistent at 7, 14, 21, 28 days; no systemic histopathologic nor hematologic changes.</td>
</tr>
<tr>
<td>RDR-0150-DS</td>
<td>Sprague-Dawley rats</td>
<td>0, 200, NO in air, with 2.6 ppm NO&lt;sub&gt;2&lt;/sub&gt; in 200 ppm NO group</td>
<td>Report of evaluation of respiratory tract at the level of electronmicroscopy from animals exposed for 28 days</td>
<td>Slight ultrastructural changes of ciliated respiratory, type 2 alveolar, and clara cells consistent with NO&lt;sub&gt;2&lt;/sub&gt; exposure.</td>
</tr>
</tbody>
</table>

*Noxivent™ (nitric oxide for Inhalation)
Praxair Canada Inc.
<table>
<thead>
<tr>
<th>Mutagenicity Reports</th>
<th>Category and Test System</th>
<th>Dose/Concentration</th>
<th>Study Type &amp; Duration</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1303/001-1052: Nitric Oxide: Reverse mutation in histidine-requiring strains of Salmonella typhimurium and tryptophan-requiring strains of Escherichia coli.</td>
<td>In vitro/ Salmonella typhimurium (TA 98, TA 100, TA 1535, TA 1537) and E. coli (WP2plcM 101, WP2uvrApKM101); with and without S-9 activation</td>
<td>Up to 5,000 ppm NO under continuous flow; ~1 ppm NO</td>
<td>Reverse mutation in bacteria</td>
<td>No toxicity</td>
</tr>
<tr>
<td>1303/007-1052 Nitrogen dioxide: Reverse mutation in two histidine-requiring strains of Salmonella typhimurium.</td>
<td>In vitro/ Salmonella typhimurium (TA 100, TA 1535) with and w/out S-9 activation</td>
<td>Up to 40 ppm NO</td>
<td>Reverse mutation in bacteria</td>
<td>Mutagenic with and without S-9 activation from 10 ppm NO</td>
</tr>
<tr>
<td>1303/002-1052 Nitric oxide: Mutation at the thymidine kinase (tk) locus of mouse lymphoma L5178Y cells using the microtitre- fluctuation technique.</td>
<td>In vitro mammalian cell culture (mouse lymphoma-L5178Y cells) using a liquid medium exposure</td>
<td>Up to 2450 ppm NO in nitrogen</td>
<td>Mutation of thymidine kinase locus in cultured mouse cells</td>
<td>Mutagenic above 125 ppm</td>
</tr>
</tbody>
</table>
Nitric oxide: Induction of chromosome aberrations in cultured Chinese hamster ovary (CHO) cells.

In vitro chromosome aberration in cultured Chinese hamster ovary cells (CHO) 
Flow thru system with up to 1800 ppm NO in nitrogen 
Mitotic inhibition and chromosomal aberration 
1650 ppm NO yielded mitotic inhibition of 52% and increase in structural damage to chromosomes.

Nitric oxide: Induction of chromosome aberrations in the peripheral blood lymphocytes of human volunteers after exposure in vivo.

In vivo human exposures 
40 ppm NO in 30% O₂ for 2 hrs 
Metaphase analysis 
No evidence of chromosomal damage


TK6 human lymphoblasts 
0.125, 0.25, 0.375 ml NO gas/ml culture medium for 1 h 
Mutation at HPRT and TK locus 
Positive mutagenesis and single-strand DNA breaks

### Chronic Toxicity and Carcinogenicity Study

<table>
<thead>
<tr>
<th>Reports</th>
<th>Species &amp; Test System</th>
<th>Dose/Concentration</th>
<th>Study Type &amp; Duration</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>N005243 Chronic Toxicity and Carcinogenicity Study of Nitric Oxide in Male and Female Rats</td>
<td>F344 Rats</td>
<td>0, 5, 20, and 20 ppm NO in air</td>
<td>Whole-body inhalation exposures for 20 hr/day for up to 2 years</td>
<td>Not carcinogenic</td>
</tr>
</tbody>
</table>
References or Selected Bibliography


5 Product Monograph, INOmax® (nitric oxide for inhalation; 100 ppm, 800 ppm), INO Therapeutics, Control No. 167232, Date of Revision: February 12, 2014.
This leaflet is part III of a three-part "Product Monograph" published when Noxivent™ was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about Noxivent™. Contact your doctor or pharmacist if you have any questions about the drug.

**ABOUT THIS MEDICATION**

**What the medicinal ingredient is:**

nitric oxide

**What the nonmedicinal ingredients are:**

Nitrogen

---

**What dosage forms it comes in:**

Noxivent™ is a drug product that is in the form of a gas and is packaged in gas cylinders in concentrations of 800 and 100 parts per million (ppm).

**WARNINGS AND PRECAUTIONS**

**Serious Warnings and Precautions**

Your baby’s doctor will examine your baby for all side effects, including:
- a decrease in the ability of the blood to carry oxygen
- an increase in the amount of inhaled nitrogen dioxide
- a worsened condition if Noxivent™ therapy is stopped too quickly

Noxivent™ is not indicated for use in the adult population. Passive exposure to Noxivent™ during pregnancy and breast-feeding should be avoided.

**INTERACTIONS WITH THIS MEDICATION**

The doctor will decide when to treat your baby with Noxivent™ and with other medicines, and will carefully supervise the treatment. Noxivent™ could be given with some medicines called “nitric oxide donors” or drugs that themselves can affect the blood’s ability to carry oxygen.

**PROPER USE OF THIS MEDICATION**

Because side effects increase with higher doses of inhaled nitric oxide therapy, your baby will be given a low dose of Noxivent™. Since Noxivent™ is a gas, the dose is measured in parts per million, or ppm. If for example the nitric oxide dose is 20 ppm, there are 20 parts of nitric oxide in 1 million parts of the inhaled gas mixture.

Your baby’s doctor will decide the correct dose of Noxivent™ and will administer Noxivent™ to your baby’s lungs through a system designed for delivering nitric oxide. This system delivers the correct amount of Noxivent™ to your baby’s lungs by diluting Noxivent™ with an oxygen/air mixture immediately before delivery.

For your baby’s safety, the delivery systems intended for administration of Noxivent™ are fitted with devices that constantly measure the amount of nitric oxide, nitrogen dioxide, and oxygen being delivered to your baby’s lungs. In addition, your baby’s blood will be tested throughout the treatment period to make sure there is no interference with the ability of the blood to carry oxygen.

Your baby’s doctor will decide how long your baby should be treated with Noxivent™. Usually a baby is on Noxivent™ therapy for 4 days or less.
Noxivent™ treatment should be stopped gradually, so that the circulation in your baby’s lungs is able to adjust to oxygen/air without Noxivent™. So when your baby’s treatment with Noxivent™ is almost finished, a gradual reduction in the amount of Noxivent™ being administered to your baby will be supervised by your baby’s doctor. Low blood pressure has been known to occur if treatment with nitric oxide is stopped suddenly without first lowering the dose.

**Overdose:**

In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

---

**SIDE EFFECTS AND WHAT DO ABOUT THEM**

Like all medicines, nitric oxide can have side effects. Your baby’s doctor will examine your baby closely for all side effects. If you notice any side effects not mentioned in this leaflet, even after your baby leaves the hospital, please inform your baby’s doctor.

**Short-term side effects**

When nitric oxide is inhaled it may cause the red blood cells to have less capacity to carry oxygen. It can also be harmful in other ways to your baby’s lungs. The doctor should be monitoring the blood for these and other effects.

In some babies with heart failure, inhaled nitric oxide may cause a worsening of the blood circulation in the heart and lungs.

If your baby has these side effects, the long-term clinical outcomes are unknown.

When your baby is receiving Noxivent™ therapy the Noxivent™ cannot be stopped too quickly. The dose of Noxivent™ will be gradually reduced because oxygen levels in your child’s blood may get worse when Noxivent™ is stopped too quickly.

Other side effects of inhaled nitric oxide may include: low blood pressure, blood in urine, high blood sugar, blood poisoning, infection, and skin infection.

Nitric oxide gas may in some cases cause blood not to clot as well and cause bleeding in the brain or lungs.

**Long-term side effects**

Studies of inhaled nitric oxide in newborn babies have not followed the babies’ condition for more than 2 years, so long-term side effect information is not definitely known. There are possibly long-term side effects that could affect the development of the lungs, brain and walking ability.

If your baby receives Noxivent™ therapy, it is recommended that you have your baby checked by a doctor periodically and monitored for normal developmental signs, including: growth, hearing, physical development, lung development, and learning development.

In order to find out more information about the long-term effects of nitric oxide therapy given to newborn babies, the company that manufactures nitric oxide has committed to Health Canada to collect additional safety information. This safety information will be collected on children at several stages in their development and will continue until they are at least 5-years old.

**Controlling side effects**

Your baby’s doctor will give the lowest Noxivent™ dose possible to try to avoid any side effects. Your baby’s doctor will check for any side effects of the Noxivent™ therapy and will decrease the Noxivent™ dose or stop the Noxivent™ therapy completely if necessary.

**This is not a complete list of side effects. For any unexpected effects while taking Noxivent™, contact your doctor.**

---

**Reporting Side Effects**

You can help improve the safe use of health products for Canadians by reporting serious and unexpected side effects to Health Canada. Your report may help to identify new side effects and change the product safety information.

**3 ways to report:**

- Online at MedEffect (http://hc-sc.gc.ca/dhp-mps/medeff/index-eng.php);
- By calling 1-866-234-2345 (toll-free);
- By completing a Consumer Side Effect Reporting Form and sending it by:
  - Fax to 1-866-678-6789 (toll-free), or
  - Mail to: Canada Vigilance Program
    Health Canada, Postal Locator 0701E
    Ottawa, ON
    K1A 0K9

**NOTE:** Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

---

**MORE INFORMATION**

**Storage**

---

*Nnoxivent™ (nitric oxide for Inhalation)*

Praxair Canada Inc.
Noxivent™ cylinders are stored at controlled room temperature 15-30 °C.

This document plus the full product monograph, prepared for health professionals can be obtained by contacting the sponsor, Praxair Canada Inc., at:

**1-800-PRAXAIR (800-772-9247)**

This leaflet was prepared by Praxair Canada Inc.
Prepared: January 22, 2016

---

*Noxivent™ (nitric oxide for Inhalation)*
Praxair Canada Inc.